VKTX
HealthcareViking Therapeutics, Inc. · Biotechnology · $4B
What is Viking Therapeutics, Inc.?
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic and endocrine disorders. It has no approved products yet and operates entirely in the research and development phase.
Viking advances a portfolio of oral drug candidates through clinical trials. Revenue does not yet come from product sales — the company funds operations through capital markets while its pipeline candidates progress through Phase II trials targeting conditions such as fatty liver disease, hip fracture recovery, type 2 diabetes, and a rare neurological disorder.
Incorporated in 2012 and headquartered in San Diego, California, Viking Therapeutics has built a pipeline targeting conditions with significant unmet medical need.
- VK2809 — thyroid receptor beta agonist for NASH and NAFLD (Phase IIb)
- VK5211 — selective androgen receptor modulator for hip fracture recovery (Phase II)
- VK0612 — oral candidate for type 2 diabetes (Phase IIb-ready)
- VK0214 — thyroid receptor beta agonist for X-linked adrenoleukodystrophy
Is VKTX a Good Stock to Buy?
UQS Score rates VKTX as Poor overall, reflecting the early-stage nature of the business.
The Risk pillar stands out as the relative bright spot, suggesting the company's balance sheet and near-term financial exposure are managed reasonably for a clinical-stage firm.
Quality, Moat, and Growth all score Weak — expected for a pre-revenue biotech — while Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does VKTX pay dividends?
No — Viking Therapeutics, Inc. does not currently pay a dividend.
VKTX does not pay a dividend. As a clinical-stage company with no product revenue, capital is directed entirely toward advancing its pipeline through clinical trials. Income-focused investors should look elsewhere.
When does VKTX report earnings?
Viking Therapeutics reports financial results on a quarterly cadence, typical for US-listed equities.
As a pre-revenue company, quarterly reports focus on cash runway, pipeline milestones, and operating expenses rather than sales or profit trends. Clinical trial readouts tend to move the stock more than earnings beats.
For the most recent quarter's results and upcoming reporting dates, visit Viking Therapeutics' investor relations page.
VKTX Price History
+545.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Viking Therapeutics, Inc.?
Based on Viking Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Viking Therapeutics do?
Viking Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for metabolic and endocrine conditions. Its pipeline targets fatty liver disease, hip fracture recovery, type 2 diabetes, and a rare neurological disorder. The company has no approved products and generates no product revenue.
Does VKTX pay dividends?
No, VKTX does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors seeking income should consider dividend-paying alternatives.
When does VKTX report earnings?
Viking Therapeutics follows a standard quarterly reporting schedule. Because it is pre-revenue, reports center on cash position and trial progress rather than sales figures. Check the company's investor relations page for the latest schedule.
Is VKTX a good stock to buy?
UQS Score rates VKTX as Poor overall. The Valuation pillar is Elevated, meaning the current price reflects high expectations for pipeline success. Risk is the only pillar rated Good. The full breakdown is available to Pro members.
Is VKTX overvalued?
UQS Score's Valuation pillar for VKTX is rated Elevated, indicating the market is pricing in considerable future success from its pipeline. For a pre-revenue biotech, valuation is driven almost entirely by clinical trial expectations rather than current fundamentals.
What is VKTX's market cap bracket?
VKTX is classified as a mid-cap stock. For a clinical-stage company with no approved products, this reflects significant market optimism about its pipeline candidates, particularly those targeting large metabolic disease populations.
Is VKTX a long-term quality indicator?
Assessed on long-term quality fundamentals, VKTX scores Poor. Without an approved product, established revenue, or a proven competitive moat, long-term quality is difficult to establish. Pipeline success could change this picture materially over time.
What is the main competitive advantage of Viking Therapeutics?
Viking's pipeline focuses on oral, tissue-selective drug candidates — a design approach that could offer tolerability advantages over existing treatments. However, UQS Score rates the Moat pillar as Weak, reflecting that no durable competitive advantage has been established yet.
Unlock Full VKTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for VKTX
- ✓Access full financial metrics and quality indicators
- ✓Compare VKTX against clinical-stage peers on standardized criteria
- ✓Track pillar changes as pipeline milestones develop
Pro Analysis
VKTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 73.0 | 0.0 | +4.0 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -3.8 |
| Apr 2, 2026 | 13.5 | 0.0 | 11.0 | 0.0 | 71.3 | 0.0 | — |
VKTX — Pillar Breakdown
Quality
— 0.0/100 (25%)Viking Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Viking Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.0/100 (15%)Viking Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Viking Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Viking Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VKTX.
Score Composition
Financial Data
More Stock Analysis
How is the VKTX UQS Score Calculated?
The UQS (Unified Quality Score) for Viking Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Viking Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Viking Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.